According to the Market Statsville Group (MSG), the global lower back pain market size is expected to grow from USD 9,314 million in 2022 to USD 16,138.2 million by 2033, at a CAGR of 5.7% from 2023 to 2033.

The lower back pain market is a rapidly growing industry driven by an increasing prevalence of lower back pain globally. According to the Global Burden of Disease report, lower back pain is the foremost cause of disability globally. It is projected that approximately 80% of adults will experience lower back pain at some point in their lives, thereby, highlighting its substantial impact on public health. The growing aging population is also a significant driver of the lower back pain market. As people age, they are more susceptible to developing degenerative conditions such as osteoarthritis and spinal stenosis, which can cause lower back pain. The increasing age of the population is leading to a higher demand for treatment options, contributing to the market's growth. Advancements in medical technology are also driving the growth of the lower back pain market. New and innovative treatments are being developed to address the various causes of lower back pain, including medication, physical therapy, and surgical options.

COVID-19 Impact on the Global Lower Back Pain Market

The impact of the COVID-19 pandemic on the Lower Back Pain Market has been the disruption of healthcare services. Due to the pandemic, many hospitals and clinics have had to prioritize COVID-19 patients, leading to the cancellation or postponement of non-emergency procedures, including those for lower back pain. This has resulted in a reduction in demand for lower back pain treatments, affecting the growth of the market. The COVID-19 pandemic has also led to changes in patient behavior. Many patients have hesitated to seek medical treatment for lower back pain due to concerns about exposure to the virus. This has decreased patient volume for lower back pain treatments, affecting the market's growth.

Scope of the Global Lower Back Pain Market

The study categorizes the lower back pain market based on type of lower back pain, diagnosis, treatment type and end-user area at the regional and global levels.

By Type of Lower Back Pain Outlook (Sales, USD Million, 2019-2033)

• Acute
• Sub-Acute
• Chronic

By Diagnosis Outlook (Sales, USD Million, 2019-2033)

• Clinical History
• Physical Examination
• Imaging Guidelines
• Assessment of Pain

By Treatment Type Outlook (Sales, USD Million, 2019-2033)

• Medication
• Physical Therapy
• Surgery
• Others

By End-User Outlook (Sales, USD Million, 2019-2033)

• Hospitals
• Clinics
• Rehabilitation Centers
• Others

By Region Outlook (Sales, USD Million, 2019-2033)

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Italy
  • France
  • UK
  • Spain
  • Poland
  • Russia
  • The Netherlands
  • Norway
  • Czech Republic
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Malaysia
  • Thailand
  • Singapore
  • Australia & New Zealand
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Rest of South America
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Northern Africa
  • Rest of MEA

Medication segment accounts for the largest market share by treatment type

Based on the treatment type, the market is divided into medication, physical therapy, surgery, and others. The medication segment accounted for the largest market share in 2022 in the global lower back pain market. This segment includes various medications used to manage lower back pain, including over-the-counter pain relievers such as nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and aspirin and prescription medications such as opioids, muscle relaxants, and antidepressants. NSAIDs are commonly used to manage lower back pain because they help to reduce inflammation and relieve pain. They are available over the counter and can be purchased without a prescription. Prescription medications like opioids, muscle relaxants, and antidepressants may also be used to manage lower back pain, particularly in severe pain or pain that does not respond to other treatments.

North America accounted for the largest market share by Region

Based on the regions, the global lower back pain market has been segmented across Europe, North America, Asia-Pacific, South America, and the Middle East & Africa. North America accounted for the largest market share in 2022. The region has a well-developed healthcare infrastructure with access to advanced diagnostic and treatment options. This is due to the high prevalence of lower back pain in the region, which is estimated to affect millions of individuals annually. The availability of various treatment options, including medications, physical therapy, surgery, and alternative therapies, also drives the market for lower back pain in North America. The region has a well-developed pharmaceutical industry, which produces a variety of pain medications for managing lower back pain. Additionally, the region has many physical therapy clinics and healthcare providers specializing in treating lower back pain.

Competitive Landscape: Global Lower Back Pain Market

The lower back pain market is a significant competitor and extremely cutthroat in the sector is using strategies including product launches, partnerships, acquisitions, agreements, and growth to enhance their market positions. Most sector businesses focus on increasing their operations worldwide and cultivating long-lasting partnerships.

Major key players in the global lower back pain market are:

• Pfizer Inc
• Johnson & Johnson Private Limited
• Sanofi
• Endo Pharmaceuticals Inc.
• Merck & Co Inc.
• Dr. Reddy’s Laboratories Ltd.
• Vertebral Technologies, Inc.
• Medtronic
• Boston Scientific Corporation
• BioWave Corporation
• Koninklijke Philips N.V.
• Astellas Pharma Inc.
• SpineThera Inc.
• CELGENE CORPORATION
• Teva Pharmaceutical Industries Ltd